A project coordinated by VTT turns plant cells into medical factories

VTT Technical Research Centre of Finland will coordinate the large EU research project called SmartCell. The four-year project focuses on developing methods for production of valuable pharmaceutical compounds using plant cells as a production host in an effective and controlled manner. The methods based on plant biotechnology are an alternative to chemical synthesis. By controlling the cell metabolism of a 'green factory', i.e. a living plant cell, it is possible to affect the production of desired high-value compounds. This kind of metabolic engineering also stimulates the cells towards producing completely new compounds.

Plants generate valuable secondary metabolic compounds, which can be used as pharmaceuticals. Most of these compounds are so complex that their chemical synthesis is not economically feasible. This is why biotechnology opens up a whole new avenue of possibilities. The SmartCell project will focus on terpene compounds, which are valuable for the pharmaceutical industry. These compounds for example are used in the treatment of cancer and malaria. The expertise and technology created during the project can be applied to a considerable extent in developing the biotechnological production of other compound groups in plants and plant cells.

"The opportunities offered by plant biotechnology could be much more extensively exploited in the pharmaceutical industry. The latest research methods can be used to intensify the production of valuable agents in plant cells; in a manner of speaking, plant cells could become real 'green factories'," says project coordinator, Chief Research Scientist Kirsi-Marja Oksman-Caldentey of VTT.

The SmartCell project brings together research partners from fourteen leading European research institutes and universities as well as three small and medium-sized and two major industrial enterprises. In addition to VTT, the project participants include e.g. VIB (Belgium), Leiden University (the Netherlands), Lleida University (Spain) and Fraunhofer IME Aachen, (Germany). The project's total budget is EUR 8.5 million, of which the EU's contribution is EUR 6 million. The contractual negotiations will soon be concluded, and the project will start in January 2009.

About VTT Technical Research Centre of Finland
VTT Technical Research Centre of Finland is the biggest contract research organization in Northern Europe. VTT provides high-end technology solutions and innovation services. From its wide knowledge base, VTT can combine different technologies, create new innovations and a substantial range of world-class technologies and applied research services, thus improving its clients' competitiveness and competence. Through its international scientific and technology network, VTT can produce information, upgrade technology knowledge and create business intelligence and value added to its stakeholders. For further information, please visit http://www.vtt.fi.

Most Popular Now

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Roche announces the European Commission approval o…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the trea...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

A soybean protein blocks LDL cholesterol productio…

A protein in soybeans blocks the production of a liver enzyme involved in the metabolism of triglycerides and low-density lipoprotein, scientists found in a recent study...

Discovery of anti-cancer chemistry makes skullcap …

The evolutionary secrets that enable the medicinal herb known as barbed skullcap to produce cancer fighting compounds have been unlocked by a collaboration of UK and Chin...